A 58-year-old with EF 35% on ACE inhibitor and beta-blocker continues to have symptoms. Which medication class confers mortality benefit and should be...

Question

A 58-year-old with EF 35% on ACE inhibitor and beta-blocker continues to have symptoms. Which medication class confers mortality benefit and should be included in foundational therapy?

Accepted Answer

Mineralocorticoid receptor antagonist

Answer

Short-acting dihydropyridine CCB

Answer

Ivabradine in all HFrEF

Answer

Loop diuretic as mortality therapy

Answer

Nitrate alone

us-abim MCQ (SBA): HFrEF Mortality Therapy

A 58-year-old with EF 35% on ACE inhibitor and beta-blocker continues to have symptoms. Which medication class confers mortality benefit and should be included in foundational therapy?